| scholarly article | Q13442814 |
| P50 | author | Paolo Vigneri | Q57012976 |
| Elena Tirrò | Q58204169 | ||
| Giuseppe Alberto Palumbo | Q61037582 | ||
| Fabio Stagno | Q39925146 | ||
| P2093 | author name string | Chiara Romano | |
| Livia Manzella | |||
| Maria Stella Pennisi | |||
| Francesco Di Raimondo | |||
| Stefania Stella | |||
| Alessandra Romano | |||
| Annamaria Fidilio | |||
| Silvia Rita Vitale | |||
| Michele Massimino | |||
| Nunziatina Laura Parrinello | |||
| Piera La Cava | |||
| P2860 | cites work | Centrosome-associated regulators of the G(2)/M checkpoint as targets for cancer therapy | Q21245716 |
| Acute lymphoblastic leukaemia | Q24602387 | ||
| Cancer statistics, 2015 | Q27860576 | ||
| CMC-544 (inotuzumab ozogamicin) shows less effect on multidrug resistant cells: analyses in cell lines and cells from patients with B-cell chronic lymphocytic leukaemia and lymphoma | Q28242286 | ||
| Cell-cycle checkpoints and cancer | Q28293996 | ||
| Regulating mammalian checkpoints through Cdc25 inactivation | Q28387035 | ||
| Antibody drug conjugates: design and selection of linker, payload and conjugation chemistry | Q28544658 | ||
| The multiple checkpoint functions of CHK1 and CHK2 in maintenance of genome stability | Q28611401 | ||
| Chk1 and Chk2 kinases in checkpoint control and cancer | Q29617706 | ||
| Induction of apoptosis by enediyne antibiotic calicheamicin thetaII proceeds through a caspase-mediated mitochondrial amplification loop in an entirely Bax-dependent manner | Q33195487 | ||
| Classification of lymphoid neoplasms: the microscope as a tool for disease discovery | Q33386690 | ||
| p53 C-terminal phosphorylation by CHK1 and CHK2 participates in the regulation of DNA-damage-induced C-terminal acetylation. | Q33734522 | ||
| Interplay between kinase domain autophosphorylation and F-actin binding domain in regulating imatinib sensitivity and nuclear import of BCR-ABL. | Q33828334 | ||
| Myeloid derived suppressor cells (MDSCs) are increased and exert immunosuppressive activity together with polymorphonuclear leukocytes (PMNs) in chronic myeloid leukemia patients. | Q33889439 | ||
| p53 controls both the G2/M and the G1 cell cycle checkpoints and mediates reversible growth arrest in human fibroblasts | Q33986335 | ||
| Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies | Q34276476 | ||
| Dysfunction of the TP53 tumor suppressor gene in lymphoid malignancies | Q35909637 | ||
| In vitro and in vivo single-agent efficacy of checkpoint kinase inhibition in acute lymphoblastic leukemia | Q36255484 | ||
| TP53 mutation predicts the poor prognosis of non-Hodgkin lymphomas: Evidence from a meta-analysis | Q36332053 | ||
| Regulation of DNA repair throughout the cell cycle | Q37088926 | ||
| Modern therapy of acute lymphoblastic leukemia | Q37827276 | ||
| Unravelling mechanisms of p53-mediated tumour suppression | Q38205099 | ||
| Preclinical and clinical development of inotuzumab-ozogamicin in hematological malignancies | Q38259006 | ||
| BCR-ABL residues interacting with ponatinib are critical to preserve the tumorigenic potential of the oncoprotein | Q38310710 | ||
| Inotuzumab Ozogamicin: First Global Approval. | Q52541382 | ||
| Transient activation of p53 in G2 phase is sufficient to induce senescence. | Q53043642 | ||
| BRIT1/MCPH1 expression in chronic myeloid leukemia and its regulation of the G2/M checkpoint. | Q53218157 | ||
| Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993. | Q53268906 | ||
| Resistance to Antibody-Drug Conjugates. | Q53695643 | ||
| Gain of function of mutant p53 by coaggregation with multiple tumor suppressors | Q57670523 | ||
| Calicheamicin gamma 1I: an antitumor antibiotic that cleaves double-stranded DNA site specifically | Q60305554 | ||
| Salvage Chemoimmunotherapy With Inotuzumab Ozogamicin Combined With Mini-Hyper-CVD for Patients With Relapsed or Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Phase 2 Clinical Trial | Q38371346 | ||
| Inotuzumab ozogamicin in the management of acute lymphoblastic leukaemia | Q38665500 | ||
| Role of inotuzumab ozogamicin in the treatment of relapsed/refractory acute lymphoblastic leukemia | Q38701163 | ||
| New monoclonal antibodies for the treatment of acute lymphoblastic leukemia | Q38927029 | ||
| IRF5 is a target of BCR-ABL kinase activity and reduces CML cell proliferation. | Q39032666 | ||
| Suppression of survivin induced by a BCR-ABL/JAK2/STAT3 pathway sensitizes imatinib-resistant CML cells to different cytotoxic drugs | Q39174444 | ||
| IRF5 promotes the proliferation of human thyroid cancer cells. | Q39364098 | ||
| New Insights in Thyroid Cancer and p53 Family Proteins. | Q39387810 | ||
| Acute lymphoblastic leukemia: a comprehensive review and 2017 update | Q39406969 | ||
| The novel calicheamicin-conjugated CD22 antibody inotuzumab ozogamicin (CMC-544) effectively kills primary pediatric acute lymphoblastic leukemia cells. | Q39484177 | ||
| Therapeutic potential of CD22-specific antibody-targeted chemotherapy using inotuzumab ozogamicin (CMC-544) for the treatment of acute lymphoblastic leukemia | Q40101776 | ||
| An evaluation of the ability of pifithrin-alpha and -beta to inhibit p53 function in two wild-type p53 human tumor cell lines | Q40371874 | ||
| Antibody-targeted chemotherapy of B-cell lymphoma using calicheamicin conjugated to murine or humanized antibody against CD22. | Q40461812 | ||
| Epratuzumab, a humanized monoclonal antibody targeting CD22: characterization of in vitro properties | Q40632014 | ||
| Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia | Q40705613 | ||
| UCN-01 in ovary cancer cells: effective as a single agent and in combination with cis-diamminedichloroplatinum(II)independent of p53 status. | Q40994759 | ||
| p53 is frequently mutated in Burkitt's lymphoma cell lines | Q41082472 | ||
| p53 mutations in Raji cells: characterization and localization relative to other Burkitt's lymphomas | Q41595478 | ||
| The Evolution of TP53 Mutations: From Loss-of-Function to Separation-of-Function Mutants | Q42323049 | ||
| Mutations of TP53 gene in adult acute lymphoblastic leukemia at diagnosis do not affect the achievement of hematologic response but correlate with early relapse and very poor survival | Q42397472 | ||
| Current treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia | Q42938334 | ||
| TP53 mutations are frequent in adult acute lymphoblastic leukemia cases negative for recurrent fusion genes and correlate with poor response to induction therapy | Q43181359 | ||
| Abrogation of the Chk1-mediated G(2) checkpoint pathway potentiates temozolomide-induced toxicity in a p53-independent manner in human glioblastoma cells | Q43513023 | ||
| Differential response of human acute myeloid leukemia cells to gemtuzumab ozogamicin in vitro: role of Chk1 and Chk2 phosphorylation and caspase 3. | Q44308345 | ||
| TP53 mutations occur in 15.7% of ALL and are associated with MYC-rearrangement, low hypodiploidy, and a poor prognosis | Q45002303 | ||
| CD22 monoclonal antibody therapies in relapsed/refractory acute lymphoblastic leukemia | Q45347246 | ||
| Defective p53 signaling in p53 wild-type tumors attenuates p21waf1 induction and cyclin B repression rendering them sensitive to Chk1 inhibitors that abrogate DNA damage-induced S and G2 arrest | Q46748294 | ||
| PRIMA-1 and PRIMA-1Met (APR-246): From Mutant/Wild Type p53 Reactivation to Unexpected Mechanisms Underlying Their Potent Anti-Tumor Effect in Combinatorial Therapies | Q47274927 | ||
| DNA damage response inhibitors: Mechanisms and potential applications in cancer therapy. | Q47725638 | ||
| Checkpoint kinase 1 is essential for normal B cell development and lymphomagenesis. | Q48250645 | ||
| Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study | Q49905062 | ||
| Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first-in-class proof-of-concept phase 2 study | Q50423643 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | inotuzumab ozogamicin | Q3799041 |
| P53 | Q7117920 | ||
| CHK1 | Q27544801 | ||
| Antibody-drug conjugates | Q37117788 | ||
| P304 | page(s) | 57 | |
| P577 | publication date | 2019-02-18 | |
| P1433 | published in | Frontiers in Oncology | Q26839986 |
| P1476 | title | Chk1 Inhibition Restores Inotuzumab Ozogamicin Citotoxicity in CD22-Positive Cells Expressing Mutant p53 | |
| P478 | volume | 9 |
| Q91588448 | Activation of the IGF Axis in Thyroid Cancer: Implications for Tumorigenesis and Treatment |
| Q100736939 | Development of synthetic lethality in cancer: molecular and cellular classification |
| Q90194104 | Molecular Alterations in Thyroid Cancer: From Bench to Clinical Practice |
| Q90192664 | TP53 Mutations in Serum Circulating Cell-Free Tumor DNA As Longitudinal Biomarker for High-Grade Serous Ovarian Cancer |
| Q89947291 | Targeting BCL-2 as a Therapeutic Strategy for Primary p210BCR-ABL1-positive B-ALL Cells |
Search more.